Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2025
Sources
Institutional record
Refreshed
2026-10-06
A
Alexander Burnett
Sourced from institutional research profiles (UAMS TRI or ARA).
High Impact
Role not yet determined
Also affiliated: University of Southern California (1998–2007); Georgetown University (1993); University of Arkansas Medical Center (2004–2024); Georgetown University Medical Center (1992–1994); USC Norris Comprehensive Cancer Center (2000–2005); Georgetown Lombardi Comprehensive Cancer Center (1992–1993)
31 h-index
76 pubs
3,698 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Alexander Burnett's research has focused on gynecologic oncology, investigating treatment strategies and molecular markers for various cancers affecting women. His work includes studies on ovarian, cervical, and endometrial neoplasms, examining both surgical and therapeutic interventions. Burnett has participated in clinical trials, such as a Phase II study of liposomal doxorubicin for refractory ovarian cancer and a randomized trial for bulky stage IB cervical carcinoma. He has also explored fertility-preserving surgical options, like radical vaginal trachelectomy for early cervical carcinoma.
Further research has delved into the molecular underpinnings of these cancers. Burnett has investigated the amplification of the c-erbB2 oncogene and racial differences in the overexpression of the epidermal growth factor type II receptor (HER2/neu) as prognostic indicators in uterine serous papillary cancer. His group has also worked on identifying gene expression profiles for uterine serous papillary carcinoma to discover novel molecular markers for diagnosis and therapy, and explored the potential of novel agents like Clostridium perfringens enterotoxin in treating chemotherapy-resistant ovarian cancer xenografts.
Burnett's scholarship metrics include an h-index of 32, with 78 total publications and over 3,700 citations, designating him as a highly cited researcher. He leads a research group and has collaborated with several colleagues at the University of Arkansas for Medical Sciences, including John L. Dornhoffer, Robert Saadi, Peter Eckard, and Gresham T. Richter.
Metrics
- h-index: 31
- Publications: 76
- Citations: 3,698
Selected Publications
-
Comparison of cost of endometrial cancer staging between robotic and vNOTES techniques (2026)
-
A pilot study utilizing hypothermia to reduce chemotherapy-induced peripheral neuropathy (2026)
-
Cochlear Implantation Outcomes in Paget’s Disease of the Bone: A Systematic Review (2026)
-
Rescue of Angiopoietin‐2 Inhibits Proliferation of Lymphatic Malformation Endothelial Cells (2025)
-
A Systematic Review of Case Reports of Spontaneous Retropharyngeal Hematoma (2025)
-
vNOTES retroperitoneal sentinel lymph node dissection for endometrial cancer staging: First multicenter international prospective case series (2024)
-
vNOTES retroperitoneal sentinel lymph node dissection for endometrial cancer staging: First multicenter, prospective case series (2024)
-
vNOTES (vaginal natural orifice transluminal surgery) gynecologic procedures in morbidly and super-morbidly obese women: five year experience (2023)
-
VNOTES (Vaginal Natural Orifice Transluminal Surgery) Gynecologic Procedures in Morbidly and Super-morbidly Obese Women: Five Year Experience for Three Surgeons (2023)
-
A new approach to radical hysterectomy: First report of treatment via vNOTES for cervical cancer (2022)
-
VNOTES (vaginal natural orifice transluminal endoscopic surgery) staging of endometrial cancer with sentinel lymph nodes (551) (2022)
-
Vaginal Natural Orifice Transluminal Endoscopic Surgery for Gynecologic and Gynecologic Oncology Procedures (2021)
-
Radiation treatment for refractory endometriosis: a 38-year-old female presenting with vaginal bleeding (2021)
-
Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) for Low-grade Endometrial Cancer: The First Fifty Patients (2021)
-
Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells (2020)
Grants & Funding
As listed on this researcher's institutional profile.
- OUHSC/GYN ONC GROUP CFDA 93-395 (Pamela Stone, PI) GOG 0240 A RANDOMIZED PHASE III TRIAL OF CISPLATIN PLUS PACLITAXEL WITH AND WITHOUT NCI-SUPPLIED BE NIH/Nat. Cancer Institute via University of Oklahoma Health Sciences Center
- Evaluation of Multiple Biomarker Assays to Estimate Risk of Ovarian Cancer in Patients Presenting with a Pelvic Mass Fujirebio Diagnostics, Inc
- 2004-27: A Phase I / II Study to Evaluate the Safety, Tolerance, and Efficacy of RSR13 (efaproxiral) Administered to Patients Receiving a Course of Ci Allos Therapeutics, Inc.
- Spectroscopic Evaluation of Cervical Neoplasia Guided Therapeutics
- AP 23573-07-205 A Randomized phase II trial of deforolimus (AP23573; MK-8669) compared to progestin in female adult patients with advanced endometrial ARIAD Pharmaceutical
- Protocol B9E-US-S302, Phase III Randomized Trial of Induction Chemotherapy with Gemcitabine and Carboplatin Followed by Paclitaxel Consolidation versu Lilly Research Laboratories
- Oral Interleukin 11 as a Countermeasure against Radiation Injury to Gut NIH
- A Randomized, Double-Blind, PlaceboControlled, Multicenter, 18 Week Pilot Study to Investigate the Neuroprotective Effect of Procrit® (Epoetin Alfa) o Ortho Biotech Products, L.P.
- A Multicenter Randomized, Parallel-Group, Placebo-controlled, Double-Blind Study with In-house Blinding to Determine the Effect of 156 Weeks of Treatm Merck & Company, Inc.
Collaboration Network
Top Collaborators
Alessandro D. Santin
University of Arkansas for Medical Sciences (US)
14 shared publications
- Amplification of c‐erbB2 oncogene
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
- Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
- Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
Showing 5 of 14 shared publications
Stefania Bellone
University of Arkansas for Medical Sciences (US)
13 shared publications
- Amplification of c‐erbB2 oncogene
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
- Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
- Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
Showing 5 of 13 shared publications
Sërgio Pecorelli
University of Brescia (IT)
13 shared publications
- Amplification of c‐erbB2 oncogene
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
- Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
- Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
Showing 5 of 13 shared publications
Michela Palmieri
University of Arkansas for Medical Sciences
10 shared publications
In database
- Amplification of c‐erbB2 oncogene
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
- High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
- Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer
Showing 5 of 10 shared publications
Martin J. Cannon
University of Arkansas for Medical Sciences
7 shared publications
In database
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
- High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
- Ovarian Tumor Ascites CD14+ Cells Suppress Dendritic Cell–activated CD4+ T-cell Responses Through IL-10 Secretion and Indoleamine 2,3-Dioxygenase
- Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
Showing 5 of 7 shared publications
Juan J. Roman
University of Arkansas for Medical Sciences (US)
6 shared publications
- Amplification of c‐erbB2 oncogene
- HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities
- Determination of HER2/neu status in uterine serous papillary carcinoma: Comparative analysis of immunohistochemistry and fluorescence in situ hybridization
- High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
- Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer
Showing 5 of 6 shared publications
Eric R. Siegel
University of Arkansas for Medical Sciences
5 shared publications
In database
- Amplification of c‐erbB2 oncogene
- Metformin Promotes Anti-tumor Biomarkers in Human Endometrial Cancer Cells
- Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
- Claudin-3 and Claudin-4: New targets for the treatment of chemotherapy resistant uterine serous papillary carcinoma using clostridium perfringens enterotoxin
- 046 Racial Differences in Overexpression of Epidermal Growth Factor Type II Receptor (HER2/NEU): A Major Prognostic Indicator and Novel Therapeutic Target in Uterine Serous Papillary Cancer
Stefania Canè
University of Arkansas for Medical Sciences (US)
5 shared publications
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer
- Human Kallikrein 6: A New Potential Serum Biomarker for Uterine Serous Papillary Cancer
- Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
- 006 Gene Expression Fingerprint of Uterine Serous Papillary Carcinoma: Identification of Novel Molecular Markers for Uterine Serous Cancer Diagnosis and Therapy
Rebecca L. Stone
Johns Hopkins University (US)
5 shared publications
- Use of Metformin in Obese Women With Type I Endometrial Cancer Is Associated With a Reduced Incidence of Cancer Recurrence
- The use of metformin in obese women with endometrial cancer may reduce the risk of cancer recurrence: A retrospective review
- Canine scent-specific detection of serous ovarian cancer
- Abstract number 7: Potential prognostic value of perineural invasion in vulvar squamous cell carcinoma
- Serine protease matriptase and CA-125 co-testing for ovarian cancer detection
Pamela Stone
Gynecologic Oncology Group (US)
5 shared publications
- Robotic Radical Trachelectomy for Preservation of Fertility in Early Cervical Cancer: Case Series and Description of Technique
- Overcoming extreme obesity with robotic surgery
- Ovarian Tumor Ascites CD14+ Cells Suppress Dendritic Cell–activated CD4+ T-cell Responses Through IL-10 Secretion and Indoleamine 2,3-Dioxygenase
- Lower Extremity Glandography (LEG)
- Robotic Radical Trachelectomy for Preservation of Fertility in Early Cervical Cancer: Description of Technique
Jan Baekelandt
Imelda Hospital (BE)
5 shared publications
- vNOTES retroperitoneal sentinel lymph node dissection for endometrial cancer staging: First multicenter, prospective case series
- vNOTES (vaginal natural orifice transluminal surgery) gynecologic procedures in morbidly and super-morbidly obese women: five year experience
- A new approach to radical hysterectomy: First report of treatment via vNOTES for cervical cancer
- VNOTES (Vaginal Natural Orifice Transluminal Surgery) Gynecologic Procedures in Morbidly and Super-morbidly Obese Women: Five Year Experience for Three Surgeons
- vNOTES retroperitoneal sentinel lymph node dissection for endometrial cancer staging: First multicenter international prospective case series
Maria Thomas
University of Arkansas for Medical Sciences (US)
4 shared publications
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
- 006 Gene Expression Fingerprint of Uterine Serous Papillary Carcinoma: Identification of Novel Molecular Markers for Uterine Serous Cancer Diagnosis and Therapy
- Claudin-3 and Claudin-4: New targets for the treatment of chemotherapy resistant uterine serous papillary carcinoma using clostridium perfringens enterotoxin
Juan José Mora Román
University of Arkansas Medical Center (US)
4 shared publications
- Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: Implications for Cetuximab-mediated therapy in recurrent/metastatic disease
- Metastatic Uterine Leiomyosarcoma Regression Using an Aromatase Inhibitor
- Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
- Claudin-3 and Claudin-4: New targets for the treatment of chemotherapy resistant uterine serous papillary carcinoma using clostridium perfringens enterotoxin
Fenghuang Zhan
University of Arkansas for Medical Sciences
3 shared publications
In database
- Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy
- Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
- 006 Gene Expression Fingerprint of Uterine Serous Papillary Carcinoma: Identification of Novel Molecular Markers for Uterine Serous Cancer Diagnosis and Therapy
Helen Kay
University of Arkansas for Medical Sciences (US)
3 shared publications
- Gene expression profiles of primary HPV16- and HPV18-infected early stage cervical cancers and normal cervical epithelium: identification of novel candidate molecular markers for cervical cancer diagnosis and therapy
- 006 Gene Expression Fingerprint of Uterine Serous Papillary Carcinoma: Identification of Novel Molecular Markers for Uterine Serous Cancer Diagnosis and Therapy
- 046 Racial Differences in Overexpression of Epidermal Growth Factor Type II Receptor (HER2/NEU): A Major Prognostic Indicator and Novel Therapeutic Target in Uterine Serous Papillary Cancer
Similar Researchers
Based on overlapping research topics
Erin Howie Hickey
University of Arkansas at Fayetteville
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Fatemeh Nouri Emamzaden
National Center for Toxicological Research
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Halle Morgan
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Baku Acharya
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Ahmad Mazin Safar
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Health disparities and outcomes
Amit Kumar Tiwari
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies